A Prospective NIS to Evaluate the Clinical Outcomes of Risarg® (Ribociclib) Combined With Endocrine Therapy or Chemotherapy in Patients With HR+HER2 - aBC in Routine Clinical Practice in the Russia
Active, not recruitingNCT06148506
Novartis PharmaceuticalsHR+HER2- Advanced Breast Cancer
Start: 2023-12-28End: 2027-06-30Updated: 2025-12-05